Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902)
Publication
, Conference
Stephens, DM; Moseley, A; Hill, B; Shadman, M; Fisch, M; Danilov, A; Ng, D; Banerji, V; Roeker, L; Brander, D; Othus, M; O'Brien, S; Erba, H
Published in: LEUKEMIA & LYMPHOMA
2023
Duke Scholars
Published In
LEUKEMIA & LYMPHOMA
EISSN
1029-2403
ISSN
1042-8194
Publication Date
2023
Volume
64
Start / End Page
S147 / S148
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Stephens, D. M., Moseley, A., Hill, B., Shadman, M., Fisch, M., Danilov, A., … Erba, H. (2023). Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902). In LEUKEMIA & LYMPHOMA (Vol. 64, pp. S147–S148).
Stephens, Deborah M., Anna Moseley, Brian Hill, Mazyar Shadman, Michael Fisch, Alexey Danilov, David Ng, et al. “Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902).” In LEUKEMIA & LYMPHOMA, 64:S147–48, 2023.
Stephens DM, Moseley A, Hill B, Shadman M, Fisch M, Danilov A, et al. Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902). In: LEUKEMIA & LYMPHOMA. 2023. p. S147–8.
Stephens, Deborah M., et al. “Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902).” LEUKEMIA & LYMPHOMA, vol. 64, 2023, pp. S147–48.
Stephens DM, Moseley A, Hill B, Shadman M, Fisch M, Danilov A, Ng D, Banerji V, Roeker L, Brander D, Othus M, O’Brien S, Erba H. Randomized, phase III study of early intervention with venetoclax and obinutuzumab ( VO) versus delayed therapy with VO in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL Study SWOG S1925; NCT#04269902). LEUKEMIA & LYMPHOMA. 2023. p. S147–S148.
Published In
LEUKEMIA & LYMPHOMA
EISSN
1029-2403
ISSN
1042-8194
Publication Date
2023
Volume
64
Start / End Page
S147 / S148
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences